Disclosed are recombinant proteins, compositions, vectors, kits, data analyses, and methods for inducing an immune response against, or detecting exposure to, SARS-CoV-2. In particular, the compositions, vectors, kits, data analyses and methods may be utilized to immunize subjects against disease associated with SARS-CoV-2 infection or to protect subjects from SARS-CoV-2 infection. In some embodiments, the recombinant proteins are useful in the production of antibodies against SARS-CoV-2, and for the detection of exposure to SARS-CoV-2.

A detection device (10), comprising a sample detection layer (1) provided thereon with a detection reagent reacted with an analyte and a result display region (18), wherein the device further comprises a symbol display layer (2) on which an indicator (21) is processed; after the indicator contacts with a gas which can change the color of the indicator, the indicator changes from a first color to a second color.

A detection method of a target molecule in a specimen includes a (target molecule)-(labeled binding molecule)-(capturing molecule) complex forming step of reacting the target molecule in the specimen, a capturing molecule that binds to the target molecule, and a labeled binding molecule that binds to the target molecule and which is labeled with an enzyme that catalyzes a reaction to produce ATP, to form a complex formed of the target molecule, the capturing molecule, and the labeled binding molecule, a step of removing the labeled binding molecules which did not bind to the target molecule, an ATP production step of producing ATP by reacting the (target molecule)-(labeled binding molecule)-(capturing molecule) complex with a substrate of the enzyme that catalyzes a reaction to produce ATP, an ATP amplification step of amplifying the produced ATP, and an ATP detection step of detecting the amplified ATP.

The present disclosure provides materials and methods for the continuous measurement of biomolecules in vivo and in real-time. The present disclosure relates more specifically to using capture agents and detection agents within a microfluidic device to detect and quantify biochemical features of biomarkers, enabling real-time detection and concentration measurements.

Disclosed are an immunoassay method capable of highly sensitively measuring amyloid β in a blood sample, and a kit therefor. The immunoassay method for amyloid β is a method of immunoassay of amyloid β in a blood sample, wherein the immunoassay is carried out in the presence of an anionic polymer such as a dextran sulfate salt or a polystyrene sulfonic acid salt. The kit for immunoassay of amyloid β in a blood sample comprises: an anti-amyloid β antibody or an antigen-binding fragment thereof; and an anionic polymer.

The invention provides a method for the immunological determination of an antibody against a drug antibody in a sample using a double antigen bridging immunoassay comprising a capture drug antibody and a tracer drug antibody, characterized in that the capture drug antibody is a mixture of said drug antibody conjugated to the solid phase at at least two different antibody sites and the tracer drug antibody is a mixture of said drug antibody conjugated to the detectable label at at least two different antibody sites.

The present invention generally pertains to methods of determining concentrations of drugs and their targets. In particular, the present invention, in part, pertains to use of a mild acidic assay condition to determine total drug and total target concentrations to mitigate either target interference or drug interference. The present invention also discloses a free target assay using a capture agent that has a lower affinity with a much slower association and dissociation rate compared to the drug.

The present invention broadly relates to the field of proteomics, bioinformatics & immunology for detection of Neurocysticercosis (NCC). More specifically, the present invention relates to an in vitro immunoassay for the diagnosis of active neurocysticercosis in biological samples. Further, the present invention relates to the identification of a novel antigen comprising of 219 amino acids of Putative lysine rich protein (PLRP) 25 kDa and its use in the detection of Neurocysticercosis. The amino acid sequences of antigenic polypeptides TSPP21 and TSPP22 are provided, polypeptides are useful as detection tool for identification of T. solium for recognizing active antigens in biological samples. In broad spectrum the invention defined here provides method for detecting active antigen in serum and urine of neurocysticercosis patients in kit formulation. In solitary cyst cases and cases where diagnosis is not clear by neuroimaging, this test will be boon in disguise.

The present disclosure provides methods and kits for detecting Group A Streptococcus in biological samples. More particularly, the present disclosure provides methods for enhancing the specificity and sensitivity of Group A Streptococcus immunoassays by including N-propionyl-D-glucosamine, 2-N-butanoyl-D-glucosamide, Bis-(2-(D-2-deoxy-glucosaminyl))-PEG3-amide, m-PEG4-glucosamine, m-PEG6-glucosamine, or m-PEG10-glucosamine. The methods and kits disclosed herein are thus useful for reliable and early diagnosis of streptococcal infections in a subject.

The present disclosure relates to compositions comprising a non-viable fecal bacterial preparation for treating various gastrointestinal-related conditions and disorders. The present disclosure also relates to stool-based compositions comprising adjuvants to facilitate the efficacy of immunomodulators such as vaccines and immunotherapies.